Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928231 | 0.85 | PARP15 (0.51) | PARP15TNKS2PARP2HCAR2CYP2C9 | |
| SCHEMBL20518803 | 0.84 | KDM4E (0.48) | PARP15TNKS2PARP2HCAR2CYP2C9 | |
| SCHEMBL20518796 | 0.84 | HCAR2 (0.43) | HCAR2CYP2C9MAPTAKR1B1CA12 | |
| SCHEMBL20518819 | 0.83 | MAPT (0.45) | PARP15TNKS2PARP2MAPT | |
| SCHEMBL20518790 | 0.81 | AKR1B1 (0.45) | HCAR2CYP2C9AKR1B1 | |
| SCHEMBL20518825 | 0.81 | HCAR2 (0.56) | TNKS2PARP2HCAR2CYP2C9AKR1B1 | |
| SCHEMBL17620982 | 0.80 | PARP15 (0.51) | PARP15TNKS2PARP2HCAR2MAPT | |
| SCHEMBL20518813 | 0.78 | ALDH1A1 (0.41) | HCAR2CYP2C9MAPT | |
| SCHEMBL17620810 | 0.76 | KDM4E (0.34) | HCAR2CYP2C9AKR1B1 | |
| SCHEMBL2929848 | 0.74 | PARP15 (0.51) | PARP15TNKS2PARP2MAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385069-B2 | Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2019-08-20 | — | — | US | claimed |
| US-20180282348-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-10-04 | — | — | US | claimed |
| US-10385069-B2 | Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2019-08-20 | — | — | US | disclosed |
| US-20180282348-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282348-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | S100B, S100P, S100A4 | PARP15 4454/4885TNKS2 1918/4885PARP2 4720/4885 |
| US-10385069-B2 | Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors | S100B, S100P, S100A4 | PARP15 4454/4885TNKS2 1918/4885PARP2 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.